Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00646958
Other study ID # RX-1741-202
Secondary ID
Status Completed
Phase Phase 2
First received March 26, 2008
Last updated February 26, 2014
Start date December 2007
Est. completion date April 2008

Study information

Verified date February 2014
Source Melinta Therapeutics, Inc.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the efficacy, safety and tolerability of RX-1741, an oxazolidinone, versus linezolid, another oxazolidinone, in the treatment of uncomplicated skin and skin structure infections


Recruitment information / eligibility

Status Completed
Enrollment 150
Est. completion date April 2008
Est. primary completion date April 2008
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Adult patients with uSSSI

- Adult (men and women) =18 years

- Females must be post-menopausal for at least 1 year or surgically sterile

- Sexually active males must use a barrier method of birth control during and for 30 days after the study

- Acceptable clinical diagnoses of uSSSI include, but are not limited to: Simple abscess, Impetiginous lesions, Folliculitis, Furunculosis, Carbuncles, Cellulitis

- The infection is accompanied by 2 or more of the following local signs and symptoms: Pain/tenderness, Swelling, Erythema, Localized warmth, Purulent drainage/discharge, Induration, Regional lymph node swelling or tenderness, Extension of redness

- A sample for microbiologic culture must be obtained from the primary infection site at the screening visit

- The patient must require and be a suitable candidate for oral antibiotic therapy in the opinion of the Investigator and be able to swallow tablets or capsules intact

- A written, voluntarily signed informed consent must be obtained from the patient prior to the initiation of any study-related procedures

Exclusion Criteria:

- Cellulitis (area greater than 10cm2), chronic or recurrent furunculosis, postoperative wound infection, leg ulcer, decubitus ulcer(s), erysipelas, progressive lymphangitis, acute paronychia or a deep tissue abscess such as pilonidal or breast abscess. Also excluded are skin infections resulting from animal bites

- Patients with a complicated skin and skin structure infection as judged by the Investigator

- Infections that can be treated by surgical incision alone according to the judgment of the Investigator

- Treatment with the following anti-infective agents prior to study drug administration: systemic antibiotic within 7 days; azithromycin within 14 days; a long-acting injectable antibiotic within 30 days

- Any infection which requires the use of a concomitant antimicrobial agent, in addition to study drug

- Concomitant topical therapy at the infection site for the period within 48 hours prior to study drug administration through TOC

- A chronic or underlying skin condition at the site of infection or infections involving prosthetic materials

- A wound secondary to burn injury or acne vulgaris

- Any infection site that requires: intraoperative surgical debridement; excision of infected area

- Documented or suspected bacteremia

- Fungal infection involving the nail bed or scalp at the primary uSSSI site

- Significant peripheral vascular disease

- An abscess at an anatomical location where the incidence of anaerobic pathogen involvement is increased

- Patient receiving a daily dose of > 15 mg of systemic prednisone or equivalent, for > 10 days within the period starting 14 days prior to study drug administration or anticipated through TOC

- Patient with known human immunodeficiency virus (HIV) infection.

- Medical history of hypersensitivity or allergic reaction to linezolid according to the judgment of the Investigator

- Patients receiving serotonergic agents, selective serotonin reuptake inhibitors (SSRIs), or monoamine oxidase inhibitors (MAOIs)

- Patients who have severe liver disease

- History of pheochromocytoma, untreated hyperthyroidism, untreated or uncontrolled hypertension, carcinoid syndrome

- Evidence of uncontrolled, clinically significant (according to the judgment of the Investigator) cardiovascular, pulmonary, metabolic, gastrointestinal, neurological, or endocrine disease; malignancy or psychiatric disorder

- Current evidence of deep vein thrombosis or superficial thrombophlebitis

- Experienced a recent clinically significant coagulopathy

- Evidence of clinically significant immunosuppression

- Patient who previously enrolled in this study

- Patient who has previously enrolled in any other clinical trial within 4 weeks of enrollment through TOC. Treatment with an investigational drug within 4 weeks prior to study drug administration

- Patient residing in a chronic care facility

- Any underlying condition or disease state that would interfere with the completion of the study procedures and evaluation of the absorption of study drug

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Radezolid
450mg PO QD
Radezolid
450mg PO BID
Linezolid
600mg PO BID

Locations

Country Name City State
United States Summa Health System Akron Ohio
United States South Florida Clinical Research Atlantis Florida
United States Mercury Street Medical Group, LLC Butte Montana
United States Southeast Regional Research Group Columbus Georgia
United States Brandywine Clinical Research Downington Pennsylvania
United States Contemporary Medicine, LLC Hinesville Georgia
United States Infectious Disease of Indiana, PSC. Indianapolis Indiana
United States Jamaica Hospital Medical Center Jamaica New York
United States Arnold Markowitz, MD., PC Keego Harbor Michigan
United States OWENS Pharma Research Center Long Beach California
United States Healthcare Partners Medical Group Los Angeles California
United States McKenzie Medical Center McKenzie Tennessee
United States Drug Research & Analysis Corp Montgomery Alabama
United States HealthCare Partners Medical Group Pasadena California
United States J. Lewis Research, Inc. Salt Lake City Utah
United States Clinical Trials of America, Inc. Shreveport Louisiana
United States Olive View- UCLA Center, Dept. Emergency Medicine Sylmar California
United States Warminster Medical Associates, P.C. Warminster Pennsylvania
United States ALL-TRIALS Clinical Research, LLC Winston-Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Melinta Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Participants With a Clinical Response of Cure To qualify as a Cure, participants were required to fulfill the following criteria: all systemic signs and symptoms of uSSSI present at screening were improved or resolved; no further antibiotic therapy was necessary for treatment of uSSSI; and there was no worsening or appearance of new signs and symptoms of uSSSI. Test of Cure (TOC), day 10-20 No
Secondary Number of Patients With Per-Patient Microbiologic Response of Eradicated The microbiological response at the patient level was considered Eradicated (documented or presumed)if no pathogens were present in repeat cultures taken from the original site of infection or a clinical response of cure precluded the ability to obtain a culturable specimen. Test of Cure (TOC), day 10-20 No
See also
  Status Clinical Trial Phase
Terminated NCT03127371 - Adjunctive Nitrous Oxide During ED Incision and Drainage of Abscess N/A
Completed NCT02240498 - Safety and Feasibility Study of Methylene Blue Photodynamic Therapy to Sterilize Deep Tissue Abscess Cavities Phase 1
Completed NCT00746109 - Study of Wound Packing After Superficial Skin Abscess Drainage Phase 4
Completed NCT00402727 - Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection Phase 3
Completed NCT00352612 - Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections Phase 4
Completed NCT00137085 - Ketamine Versus Fentanyl as an Adjunct to Propofol-Assisted Emergency Department Procedural Sedation N/A
Completed NCT02714023 - Water And Saline Head-to-head In The Blinded Evaluation Study Trial N/A
Completed NCT02264392 - US Guided Versus BlindI&D for Treatment of Soft Tissue Abscesses in the ED N/A
Active, not recruiting NCT05226260 - Decreasing Antibiotic Duration for Skin and Soft Tissue Infection Using Behavioral Economics in Primary Care N/A
Withdrawn NCT04241471 - Incision and Loop Drainage Utilizing a Novel Technique for Management of Cutaneous Abscess in an Adult Population N/A
Recruiting NCT06284473 - Ketamine as a Supplement to Local Anesthesia for Minor Procedures Phase 4
Completed NCT01235546 - Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection N/A
Withdrawn NCT00900510 - Antibiotic Therapy After Incision and Drainage for Abscess N/A
Not yet recruiting NCT03917134 - Prevention of Vaginal Cellulitis or Vaginal Cuff Abscess After Laparoscopic Hysterectomy N/A
Withdrawn NCT02703233 - Effectiveness of Nitrous Oxide in the ED Phase 4
Completed NCT01557426 - Soft Tissue Ultrasound of Infections Phase 1
Completed NCT01339091 - Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections Phase 3
Completed NCT01784458 - Clinical Significance of Intra-abdominal Hypertension in Surgical Patients With Severe Sepsis N/A
Terminated NCT00867789 - Antibiotics Versus Placebo in the Treatment of Abscesses in the Emergency Department N/A
Completed NCT00984022 - Aquacel Versus Iodoform Gauze for Filling Abscess Cavity Following Incision and Drainage Phase 2